Communication about an Ongoing Safety Review of Stimulant Medications used in Children with Attention-Deficit/Hyperactivity Disorder (ADHD)
Links shared publicly online about this topic.
- 380total visits
Communication about an Ongoing Safety Review of Stimulant Medications used in Children with Attention-Deficit/Hyperactivity Disorder (ADHD)
fda.gov —
View full resource at fda.gov
Tags: ADHD, Disease and Condition, Drug, Healthcare, Children's Health, FDA, Safety
Most Recently Shared on April 8, 2011 at 3:30 pm By:
FDA Info 4 Healthcare Professionals Ongoing Safety Review of Stimulant Medications used in Children with (ADHD) http://t.co/H0vdAnI
FDA Issues Safety Communication about an Ongoing Review of Stimulant Medications Used in Children with ADHD
fda.gov — “There may be an association between the use of stimulant medications for attention- deficit hyperactivity disorder, known as ADHD, and sudden cardiac death in healthy children, according to a study published in the American Journal of Psychiatry. But the U.S. Food and Drug Administration says that, because of the study's limitations, parents should not stop a child's stimulant medication based on the study. The FDA recommendsthat parents should discuss concerns about the use of these medications” View full resource at fda.gov
Most Recently Shared on June 15, 2009 at 4:19 pm By:
eyeonfda Pharma and Health Lawyer
FDA Issues Safety Communication about an Ongoing Review of Stimulant Medications Used in Children w/ADHD - http://bit.ly/CwgvG
Communication about an Ongoing Safety Review of Stimulant Medications used in Children with Attention-Deficit/Hyperactivity Disorder (ADHD)
fda.gov — “Link to Drug@FDA added for current labeling information.” View full resource at fda.gov
Most Recently Shared on June 15, 2009 at 3:19 pm By:
Physician Assistants Health News Feed
Stimulants used for ADHD may be associated with increase in sudden unexplained deaths in young: http://tinyurl.com/m2djga Am J of Psychiatry
Advertisement
